Form PTO-1390-MOD U. S (REV 10-96)	ATTORNEY'S DOCKET NUMBER OP/4-32592A									
TRANSMITTAL LETTER TO	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
DESIGNATED/ELECTED O	Not Yet Assigned									
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371										
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE 22 July 2003 (22.07.03)	PRIORITY DATE CLAIMED								
PCT/EP03/08005	23 July 2002 (23.07.02)									
TITLE OF INVENTION OPHTHALMIC OINTMENT COMPOSITION	COMPRISING A DRUG, AN OINTM	IENT BASE AND A								
SOLUBILIZING/DISPERSING AGENT										
APPLICANT(S) FOR DO/EO/US										
AUKUNURU ET AL.										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
<ol> <li>This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> </ol>										
<ol> <li>A proper Demand for International earliest claimed priority date.</li> </ol>	al Preliminary Examination was n	nade by the 19th month from the								
<ul> <li>5.  \( \text{\text{\$\text{\$A}}} \) A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul> <li>a.  \( \text{\$\text{\$\text{\$\text{\$\text{\$I}}}} \) is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b.  \( \text{\$\text{\$\text{\$\text{\$\text{\$I}}}} \) has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> <li>c.  \( \text{\$\text{\$\text{\$\text{\$\text{\$I}}}} \) is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </li> <li>6.  \( \text{\$\text{\$\text{\$\text{\$\text{\$I}}}} \) Attensitation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7.  \( \text{\$\text{\$\text{\$\text{\$\text{\$I}}}} \) Amendments to the claims of the International Application under PCT Article 19 (35).</li> </ul>										
U.S.C.371(c)(3)).  a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).  b. ☐ have been transmitted by the International Bureau.  c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.  d. ☐ have not been made and will not be made.  8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).  9. ☐ An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).  10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
Items 11. to 16. below concern document(s) or information included.										
11. An Information Disclosure Stat	tement under 37 CFR 1.97 and	1.98.								
12. An assignment document for reco	ording. A separate cover sheet in	n compliance with 37 CFR 3.28								
13. A FIRST preliminary amendme  A SECOND or SUBSEQUENT pre										
14. A substitute specification.										
15. A change of power of attorney ar	nd/or address letter.									

16. 🛛 Other items or information: Application Data Sheet, Unexecuted Declaration and Post Card.

: 1

DT01 Rec'd PCT/FT3 2-1 JAN 2005

U.S. APPLICATION TO. (if	(if nom, see 37CFO : INTERNATIONAL APPLICATION NO.			NEY'S	NEY'S DOCKET NUMBER				
21.   The following fees are submitted:						CALCULATIONS PTO USE ONLY			
,									
a) Basic national fee									
b) Examination fee \$200									
c) Search fee								<b>T</b>	
TOTAL OF ABOVE CALCULATIONS =							\$ 1000		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper									
computer pro		isting tilea ir	i an electr	onic medium). Ti	ne ree is \$2	ou for each a	additional 50 s	neets of paper	
Total Sheets	The state of the s			RATE					
28 - 100 :	_	/50		ereor (round <b>up</b> (		umber)	× \$ 250	\$	
20-100	1		<u> </u>		·		1 1 4 200	<del>  *</del>	
Surcharge of \$130 for furnishing the oath of declaration later than   20   30  months from the earliest claimed priority date (37 CFR 1.492(e)).							\$		
CLAIMS	·		R FILED	NUMBER		R	ATE		
Total claims		26	- 20	= 6		X \$	50	\$ 300	
Independent claim		1	- 3			X \$	200	\$	
MULTIPLE DEPE	NDENT	CLAIM(S)	(if applical			+ \$	360	\$	
				TOTAL O	F ABOVE	CALCUL	ATIONS =	\$	
Reduction of 1/2 for			tity, if app	licable. Verified S	Small Entity	Statement m	nust also be		
filed (Note 37 CFF	1.9 <u>, 1.</u>	27, 1.28).						\$	
							BTOTAL =	\$ 1300	
Processing fee of \$130 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$			
					TOTA	L NATIO	VAL FEE =	\$ 1300	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied									
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$			
TOTAL FEES ENCLOSED =							\$ 1300		
							Amount to be:	Ī \$	
						refunded	T .		
								charged	
a. A check in the amount of \$ to cover the above fees is enclosed.									
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$ to cover the above fees. A duplicate copy of this form is enclosed.									
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
				-41 244.					
Send all correspondence to the address associated with Customer No. 001095, which is currently:									
Susan Hess									
. Novartis						rney for Appl			
Corporate Intellectual Property Reg. No. 37,350									
One Health Plaza, Building 104 (862) 778-7859 East Hanover, NJ 07936-1080									
East Hallovel, NO 07300-1000									